Am­gen vet's new biotech nets $47M Se­ries A for poly­mer-based AD­Cs

Cal­i­for­nia-based can­cer start­up Dan­tari an­nounced a $47 mil­lion Se­ries A fi­nanc­ing Thurs­day in its push to de­vel­op an­ti­body-drug con­ju­gates with its own spin on the treat­ments.

The com­pa­ny’s main can­di­date is called DAN-222, and it’s be­ing eval­u­at­ed in a Phase I/II clin­i­cal tri­al for the treat­ment of metasta­t­ic hu­man epi­der­mal growth fac­tor re­cep­tor (HER) 2-neg­a­tive breast can­cer.

Tra­di­tion­al AD­Cs are lim­it­ed in their ca­pa­bil­i­ties; when at­tach­ing the chemother­a­py to the an­ti­body, there’s on­ly about eight bind­ing sites that can be used. Any more than that, and it starts in­ter­fer­ing with the an­ti­body’s func­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER